Meanwhile, MYBL2 overexpression has been observed in cancers such as bladder cancer [19] and prostate cancer [19], and it is currently used as a biomarker for poor prognosis in ovarian carcinoma [20]. This evidence concerns the gene MYBL2 and cancer.